GJB2 and hearing loss disorder: The distribution of homozygous p.V37I variation or compound p.V37I plus other GJB2 pathogenic mutation (2.75%) in the patient groups was significantly higher than that in the control group (0%) (Table 2), suggesting that the presence of p.V37I variation was more frequently associated with hearing loss.